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Abstract
Background: Worldwide obesity has nearly doubled since 1980 and is a leading risk for global deaths, profoundly
affecting morbidity, mortality, health-care costs, and professional and personal quality of life. Treatment of obesity
and its consequences include lifestyle intervention, pharmacotherapy, and bariatric surgery. Polyglucosamines have
been proposed as an alternative strategy for treating obesity, by reducing the amount of absorbed fat through
interaction with dietary fat through various mechanisms. The objective of this study is to investigate the influence
of polyglucosamine on the bioavailability of the model compound [9-14C]-oleic acid in female Göttingen minipigs.
Method: The study consisted of two treatment groups, each consisting of six adult female Göttingen minipigs with
a catheterized vena jugularis to enable frequent blood sampling. One group served as the untreated group (control)
and the other group was pre-treated with 2 tablets of 500 mg formoline L112. After 30 min, all animals were
dosed orally with [9-14C]-oleic acid. Excreta and blood samples were collected for analysis of radioactivity from 48 h
pre-dose up to 144 h post-dosing. At sacrifice, the liver and contents of the gastrointestinal tract were collected for
radioanalysis.
Results: Upon treatment with polyglucosamine (formoline L112), the Tmax of [
14C]-oleic acid in plasma was shifted
from 4 to 16 h, and the Cmax decreased significantly from 14.1 μg/g to 3.3 μg/g. In addition, upon treatment
with polyglucosamine the internal exposure to [14C]-oleic acid as reflected by the area under the curve during the
0–12 h post-dose time interval (AUC0-12h), is significantly decreased to 32.9 % of the plasma value of [
14C]-oleic acid in
untreated animals. Even up to 24 h post-dose, the AUC0-24h is significantly decreased to 50.7 % of the plasma value in
untreated animals and this significant effect is prolonged up to 60 h post-dose.
Conclusions: This study shows that treatment with polyglucosamine (formoline L112) reduces (as judged by Cmax &
AUC) and delays (as judged by Tmax) fat absorption from the gastrointestinal tract into the systemic circulation and
limits peak exposure to free fatty acids which may contribute to a more beneficial condition in overweight humans.
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Background
Worldwide obesity has nearly doubled since 1980. In
2008, more than 1.4 billion adults, 20 and older, were
overweight. Of these, over 200 million men and nearly
300 million women were obese. About 65 % of the
world’s population lives in countries where overweight
and obesity kills more people than underweight. Over-
weight and obesity are leading risks for global deaths.
Around 3.4 million adults die each year as a result of
being overweight or obese. In addition, 44 % of the dia-
betes burden, 23 % of the ischemic heart disease burden
and between 7 and 41 % of certain cancer burdens are
attributable to overweight and obesity [1]. Obesity pro-
foundly affects morbidity, mortality, health-care costs,
and professional and personal quality of life [2].
The current strategies to reduce the burden of this dis-
ease and its consequences include lifestyle intervention
(diet/physical activity), pharmacotherapy, and bariatric sur-
gery. The strict requirements with respect to efficacy and
safety have resulted in very limited pharmacotherapeutic
options. As of September 2013, only three drugs are ap-
proved by the FDA as adjunctive therapy for chronic
weight management: 1) the intestinal lipase inhibitor orli-
stat, 2) lorcaserin acting via the serotonergic system and 3)
a phentermine/topiramate extended-release formulation,
acting via modulation of catecholamines in the satiety cen-
ters of the hypothalamus, reducing appetite (phentermine)
and blocking voltage-dependent sodium channels, glutam-
ate receptors, carbonic anhydrase, and augmenting GABA
activity (topiramate) [2–4]. Still there exist potentially haz-
ardous effects as well as certain unpleasant side-effects.
The side-effects resulting from orlistat’s mode of action
include oily spotting, liquid stools, fecal urgency or incon-
tinence, flatulence, and abdominal cramping [5]. Major
concerns on lorcaserin include cardiovascular events,
cognitive impairment, and psychiatric disorders [2, 4].
Approval of the phentermine/topiramate cocktail was
denied by European regulatory authorities, who cited
potential risk to the heart and blood vessels, psychi-
atric side effects, and cognitive side effects in explain-
ing their decision [6].
At present, because of dissatisfaction with high costs
and potentially hazardous and/or unpleasant side-effects,
the potential of natural products for treating obesity is
under exploration, and this may be an excellent alternative
strategy for treating obesity [3]. There are numerous
nutraceutical products to consider incorporating into a
weight management program. Among soluble fibers, one
such polysaccharide is chitosan [7]. Chitosan has the
potential to be a safe compound for oral use [8, 9]. The
FDA has judged Chitosan a GRAS (Generally Recognized
As Safe). Chitosan polymers are not absorbed by the GIT
and are unlikely to show biodistribution [9]. Chitosan has
been promoted as a type of dietary fiber that may help
reduce the absorption of fat due to its ability to
“bind” fat and bile salts in the human gastrointestinal
tract and pass this complexed fat-chitosan mixture
out the body. This action reduces absorbed fat, and
has prompted the use of these substances to help
with weight loss [7].
The hypocholesterolemic and lipid lowering effects of
chitosan are well recognized, but the specific mechanisms
are not fully understood. The activity of polyglucosamine
has been related to its positively charged amino-groups
resulting in binding to free fatty acids (released from con-
sumed fat) and bile salt components which results in dis-
rupted lipid absorption in the gut. It has been suggested
that polyglucosamine dissolves in the stomach, emulsify-
ing fat and forming a gel in the intestine which entraps fat
and prevents intestinal absorption. More recently, it has
been proposed that polyglucosamine forms a flocculus in
the duodenum which entraps dietary oil [8, 10, 11]. In
addition, it has been suggested by in vitro experiments
that chitosan might act as a competitive inhibitor of pan-
creatic lipase [12]. Overall, the mechanisms involved in
chitosan’s interaction with dietary fat involve a combin-
ation of the above stated mechanisms, but none specific-
ally have been confirmed [7, 13, 14].
Whether chitosan is actually clinically effective in
cholesterol control or weight loss remains controver-
sial. Various studies indicate that chitosan dietary
supplementation had no effect on fat absorption or
plasma cholesterol levels and had only a minimal, clin-
ically insignificant, effect on bodyweight [15–19].
Other studies, however, have reported reduced blood
cholesterol, lowered weight, a reduced percentage of
fat and fat mass in the clinic upon chitosan supplementa-
tion [20–24]. In addition, it has been shown that 3-
months administration of chitosan significantly increased
insulin sensitivity in obese patients and expressed a
highly notable decrease in bodyweight and triglyceride
levels [25].
Formoline L112 is a linear polysaccharide composed of
randomly distributed β-(1–4)-linked D-glucosamine (dea-
cetylated unit) and N-acetyl-D-glucosamine (acetylated
unit) from crustacean shells. Therefore, the formoline
L112 is one dedicated specification of low molecular
weight chitosan and due to its high degree of deacetylation
it is part of the subgroup of polyglucosamines [13, 14].
Formoline L112 is registered as a class III medical device
in Germany, and is used to limit fat absorption. The
extremely high fat binding capacity of polyglucosamine
has been demonstrated in vitro mimicking the envir-
onment of the gastrointestinal tract. One gram of
formoline L112 has been demonstrated to bind about
700 g of dietary fat [7]. Formoline L112 is used for
weight management, weight loss and to lower choles-
terol blood levels. The efficacy of polyglucosamine
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formoline L112 for weight loss was confirmed in a
randomized double-blind, placebo-controlled clinical
investigation [24].
Although formoline L112 has been demonstrated to
bind large amounts of dietary fats in vitro, the impact of
polyglucosamine on the availability and uptake of lipids
in the in vivo situation remains to be established.
The objective of this study is to provide data on
the influence of formoline L112 on the bioavailability
of [9-14C]-oleic acid (CH3(CH2)7CH=CH(CH2)7COOH)
as model compound. In chemical terms, oleic acid is clas-
sified as a mono-unsaturated omega-9 fatty acid. The
model compound oleic acid is a fatty acid that occurs
naturally in various animal and vegetable fats and oils. Tri-
glycerides of oleic acid compose the majority of olive
oil. Oleic acid is the most abundant fatty acid in human
adipose tissue [26]. Oleic acid is an unsaturated fatty
acid which could easily be labelled on a specific pos-
ition in the molecule which allows a good tracing of the
active compound.
The minipig was selected to explore the effects of
the fat binding polyglucosamine on the bioavailability
of the model compound oleic acid. This is based on
the knowledge that various anatomical and physio-
logical aspects of (mini)pigs resemble more the human
situation than other animal species. The minipig is
emerging rapidly as a biomedical model for energy
metabolism and obesity in humans, because it is de-
void of brown fat postnatally and because of their
similar metabolic features, cardiovascular systems, and
proportional organ sizes [27, 28]. Both humans and
(mini)pigs are true omnivores. This is reflected in the
anatomy, physiology and function of the gastrointes-
tinal system, and despite some anatomical differences
in the (mini)pig the physiology of digestion remains
similar to humans [29–31]. The small intestine is long,
with a transit time and pH profile very similar to
humans. In a recent study the mean retention time in
the small intestine for 30 kg pigs was estimated to be
4 h [32]. Enzyme activity in the gut and absorption
show many similarities [33]. The bioavailability of
orally administered drugs that are influenced by pH or
transit time can be expected to be comparable in
humans and (mini)pigs. Moreover, from information
in the public domain as well as publications from the
European Medicines Agency (EMA) and the FDA, it is
clear that the minipig is fully recognized and accepted
by regulatory authorities worldwide [33]. The minipig
has a significant advantage over the pig because of the
reduced size, thus reducing the amount of radiola-
belled compound needed for the experiments and
allowing easier handling, especially as adult animals
are required [33]. For the present study, adult minipigs
are preferred as in younger animals there is no fat
storage within the first year, since they will metabolize




Oleic acid (purity 99 %) was purchased from Sigma-
Aldrich Chemie GmbH (Germany). [9-14C] Oleic acid
was custom synthesized at Moravek Biochemicals Inc.
(US). The specific activity was 19.5 mCi/mmol and
purity was 99.7 %. Polyglucosamine (formoline L112
(C12H24N2O9 (C6H11NO4)n(C7H13NO3)n), tablets of
500 mg) was obtained from Certmedica International
GmbH (Germany).
Animal model
The study was conducted with 12 female Göttingen Mini-
pigs aged approximately 13–14 months. The welfare of
the animals was maintained in accordance with the gen-
eral principles governing the use of animals in experi-
ments of the European Communities (Directive 86/609/
EEC) and Dutch legislation (The Experiments on Animals
Act, 1997). This includes approval of the study by TNO’s
independent ethical review committee (DEC nr. 3329).
The minipigs were obtained from Ellegaard Göttingen
Minipigs A/S, Dalmose (Denmark). Upon arrival, the
minipigs were checked for overt signs of ill health and
anomalies. The animals were kept in indoor pens, ac-
cording to European guidelines for housing of labora-
tory minipigs. The age of the minipigs at start of the
study was approximately 14 months. At the commence-
ment of the study, the weight variation of the animals
did not exceed ± 20 % of the average weight.
A cannula was placed in the vena jugularis, while the
animals were under anaesthesia. Animals received 13 mg/
kg ketamine, 0.7 mg/kg midazolam, 0.02 mg/kg atropine
and 4 mg/kg thiopental as premedication and amoxycil-
line/clavulanic acid as antibiotic treatment with depomy-
cine around the catheter area.
Following cannulation, the animals were acclimatized
to the laboratory conditions for at least 14 days. The
minipigs were randomly allocated to a study treatment,
with randomization restricted to bodyweight.
Each study group was housed in one pen. During the
acclimatization period, the minipigs were socialized and
trained prior to the study in order to minimalize stress and
obtain collaborative animals. The animals were housed
under conventional conditions in indoor pens on straw
bedding with a playing ball during acclimatization. Animals
were acclimatized to the stainless steel metabolism cages
under test conditions, 48 h prior to the experimental start
date (dosing). The room was ventilated with approximately
10 air changes per hour and targeted at a temperature of
20–24 °C with a relative humidity of 45–70 %. Lighting
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was artificial with a sequence of 12 h light and 12 h dark.
Animals were checked twice daily for signs of ill health.
The animals were fed a commercial diet (SMP (E)
SQC) (SDS Special Diets Services, Whitham, England)
and received a measured amount of food (225 gr per
meal) twice daily (in the morning and in the afternoon/
early evening (at dosing day; about 8 h post-dosing).
Fourteen days prior to the experimental start date (dos-
ing), the standard diet was supplemented with approxi-
mately 10 g of olive oil per meal. Drinking water was
supplied by N.V. Vitens Midden-Nederland and offered
ad libitum at all times.
Study design
The study consisted of two treatment groups, each con-
sisting of six female Göttingen minipigs. Group A served
as the untreated group (control) and group B was pre-
treated with polyglucosamine as follows; the animals of
group B were dosed with 2 tablets of 500 mg formoline
L112 (1 g formoline L112 in total) followed by approxi-
mately 10 ml of water via a syringe. The 2 tablets of
polyglucosamine were inserted into 2 gelatine capsules.
The minipigs were trained to eat these capsules. There-
after, animals of both groups were allowed to drink
water ad libitum. After 30 min, all animals were dosed
by oral ingestion of gelatine capsules containing the
proper amount of test substance [9-14C]-Oleic acid
(10.8 μCi (0.4 MBq) [9-14C]-Oleic acid per kg body-
weight and 10 mg oleic acid per kg bodyweight) using a
special dosing device and a wooden block preventing the
animals to bite into the capsules. One animal of the con-
trol group A was inadequately dosed and was omitted
from the experiment. The dosing capsules were prepared
the day before the dose administration based on the
bodyweight determined shortly before dosing and stored
under nitrogen and protected from light at 2–10 °C. Im-
mediately following dosing all animals received approxi-
mately 10 ml of water via a syringe. After 15 min,
animals were allowed to drink water and eat their morn-
ing meal. This meal was eaten within a few minutes. The
animals were housed in stainless steel metabolism cages
under test conditions, 48 h prior to the experimental
start date (dosing).
Sampling schedule
Urine and faeces was collected at ambient temperature
at 24 h time intervals, starting at 2 days prior to dosing
and ending at 144 h post-dose. At each collection
period, the cage was rinsed with 100 mL demi-water. At
various defined time points blood samples of approxi-
mately 5 mL were taken via the cannula in the jugular
vein into tubes with heparin as anticoagulant at pre-
dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 96, 120
and 144 h post-dosing of [9-14C]-Oleic acid. The
cannula was rinsed with physiological saline after each
blood sampling. After the last blood sampling of the day
the cannula was filled with 3 % poly vinyl pyrrolidone
(PVP) and heparin, and closed with a lid. Subsamples of
whole blood were collected for analysis and the remaining
blood was used for preparation of plasma by centrifuga-
tion for 10 min at 2000 g. At the end of the experiment,
the cages were rinsed thoroughly with water/ethanol/
Triton X-100 (100/100/1; v/v/v). The minipigs were
intravenously anaesthetized via the catheter with 60 mg
sodium-pentobarbital per kg bodyweight. Next, the ani-
mals were sacrificed by exsanguination from the carotid
artery. At sacrifice, the complete liver and contents of the
gastrointestinal tract were collected. Prior to analysis of
radioactivity, the faeces, liver and contents of the gastro-
intestinal tract were homogenized using an ultrathurrax.
Analysis of radioactivity
Radioactivity in all samples was determined by liquid
scintillation counting on a Tri-Carb 3100TR liquid scin-
tillation counter using QuantaSmart™ software. All
counts were converted to DPM using tSIE/AEC (trans-
formed Spectral Index of external standards coupled to
Automatic Efficiency Correction). Radioactivity in faeces,
blood and liver tissue was determined by combustion ana-
lysis using a Packard Sample Oxidizer System 307. The
CO2 formed was mixed with Carbosorb™ and Permafluor™
and measured by LSC.
HPLC analysis for metabolic profiling
The HPLC system consisted of a Spectra Series P200
binary gradient pump from Thermo Separations and a
Lablogic ß-RAM detector Model 4 in combination with
Laura™ software and UV detection at 210 nm. HPLC
analysis was achieved using a reversed phase BDS
Hypersil C18 column (5 μ, 250 × 4.6 mm) eluted at a
flow of 1 mL/min with 0.1 % formic acid in water as
eluent A and 0.1 % formic acid in acetonitrile as eluent
B. The flow of the scintillation fluid (Ultima-Flo™ M)
was 3 ml/min. Radioactivity in faeces was extracted with
acetonitrile before HPLC analysis. The residue was dis-
solved in DMSO : tetrahydrofuran (1:1; v:v) and was
injected directly on the HPLC column.
Pharmacokinetic and statistical analysis
Kinetic analysis of radioactivity (blood/plasma) was per-
formed using WinNonlin® 6.3 applying non-compartmental
model analysis. The following kinetic parameters were cal-
culated where the data allow: Cmax, Tmax, half-life (t1/2),
the volume of distribution, clearance, the Area under the
concentration-time curve (AUC) (or AUC0-n, AUC0-∞)
and the Mean Residence Time (MRT). Statistical analysis
was assessed by using Mann–Whitney U-test (non-para-
metric test) using the Brightstat [34].
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Results
Dose administration and animal observation
In order to investigate the influence of the polyglucosa-
mine formoline L112 on the bioavailability of [14C]-oleic
acid, female Göttingen minipigs were orally dosed with-
out (group A) or with polyglucosamine formoline L112
(group B) followed by a single dose of [9-14C]-oleic acid.
The administered dose levels of oleic acid were between
9.78 and 10.0 mg/kg, which was close to the intended dose
levels of 10 mg/kg bodyweight. The dosed amount of
radioactivity was between 0.42 and 0.43 MBq/kg, which
was closed to the intended dose of 0.4 MBq/kg body-
weight. Body weights were determined during acclimatisa-
tion, at the day of start acclimatisation to the metabolism
cages and at sacrifice (Table 1). Weight loss was not an
objective of the present study as the [14C]-oleic acid and
formoline L112 was only given in a single dose to monitor
effects of L112 on the bioavailability of [14C]-oleic acid.
The animals were checked for appearance and behav-
iour during acclimatisation, during treatment and at each
sampling time. No study- or test substance-related signs
of toxicity or unusual behaviour were observed. Formoline
L112 did not cause any effect on faecal excretion; oily
spotting, liquid stools, fecal urgency or incontinence,
flatulence, and abdominal cramping, as frequently ob-
served during anti-obesity treatment with an intestinal lip-
ase inhibitor [5], was not observed in both treatment
groups. No abnormalities were observed at autopsy.
The influence of pre-treatment with the polyglucosamine
formoline L112 on the pharmacokinetic behaviour of
orally dosed [14C]-oleic acid in the Göttingen minipig
Following pre-treatment with or without formoline
L112, minipigs were orally dosed with 10 mg [14C]-oleic
acid/kg bodyweight. Blood samples were collected dur-
ing a 144 h blood sampling period and radioactivity
(representing [14C]-oleic acid and/or its metabolites) was
determined in blood and plasma.
Figure 1 represents the mean plasma concentrations of
radioactivity (μg oleic acid equivalents and/or its metab-
olites/g plasma) versus time curve for the female
minipigs after a single oral dose of 10 mg/kg [14C]-oleic
acid to untreated control animals (group A) and animals
pre-treated with formoline L112 (group B). The un-
treated animals of group A showed a clear peak of radio-
activity (oleic acid equivalents and/or its metabolites)
between 0 and 24 h, which declined considerably follow-
ing pre-treatment with formoline L112.
Figures 2 presents the individual time versus radioactivity
concentration expressed as μg parent compound equiva-
lents/g plasma of female Göttingen minipigs after a single
oral dose of [9-14C]-oleic to animals that were pre-treated
with formoline L112. In these plasma profiles a clear effect
of a partial stomach emptying was observed around the
time-points of feeding at start and end of the day, around 8
and 24 h post-dose. This effect was not observed for the
untreated animals of group A. At the second emptying
period of the stomach, the binding strength of formoline
L112 for [14C]-oleic acid is clearly still present.
The plasma and blood kinetic data for [14C]-oleic acid
(μg oleic acid equivalents and/or its metabolites/g) were
analysed and were shown to best fit a non-compartmental
model using the WinNonlin pharmacokinetic software
program. The data could not be fitted to other kinetic
models for both the untreated animals of group A and the
formoline L112 treated animals of group B. The calculated
pharmacokinetic parameters for [14C]-oleic acid of group
A and group B are presented in Table 2 and are clearly af-
fected upon treatment with formoline L112.
Upon treatment with formoline L112, the concentration
of [14C]-oleic acid in plasma reaches its maximal value at a
significantly later time-point namely 16 h post-dose com-
pared to untreated animals, where the Tmax occurred at
4 h post-dose. The maximal concentration of [14C]-oleic
acid in plasma decreases significantly from 14.1 μg/g to
3.3 μg/g upon treatment with formoline L112. In addition,
upon treated with formoline L112 the internal exposure to
[14C]-oleic acid as reflected by the area under the curve
during the 0–12 h post-dose time interval (AUC0-12h), is
significantly decreased to 32.9 % of the plasma value of
[14C]-oleic acid in untreated animals. Even up to 24 h
post-dose, the AUC0-24h is significantly decreased to
Table 1 Bodyweights and dose levels of [9-14C]-oleic acid administered to untreated female Göttingen minipigs (group A - control)
and female Göttingen minipigs that were pre-treated with 2 tablets of 500 mg formoline L112 (group B – formoline L112)
Group A - control Group B - formoline L112
Animal number A1 A2 A3 A4 A5 Mean ± SD B1 B2 B3 B4 B5 B6 Mean ± SD
Body weight (kg):
At acclimatisation 25.6 30.1 34.5 31.7 28.3 30.0 ± 3.4 32.2 30.0 31.4 30.5 33.9 31.4 31.6 ± 1.4
At dosing 26.0 27.7 31.9 31.3 27.6 28.9 ± 2.6 32.2 31.4 28.8 30.5 31.6 31.2 31.0 ± 1.2
At sacrifice 25.8 27.2 31.8 30.0 27.4 28.4 ± 2.4 32.9 29.6 28.2 28.2 30.4 30.0 29.9 ± 1.7
Dose (mg/kg) 9.78 9.89 9.92 9.92 9.89 9.88 ± 0.06 10.0 9.88 9.91 9.91 9.92 9.93 9.93 ± 0.04
Radioactivity (MBq/kg) 0.42 0.43 0.43 0.43 0.43 0.43 ± 0.00 0.43 0.43 0.43 0.43 0.43 0.43 0.43 ± 0.00
Values are presented as individual and mean ± standard deviation
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50.7 % of the plasma value in untreated animals and this
significant effect is prolonged up to 60 h post-dose. With
regards to the concentrations of radioactivity in blood a
similar pattern was observed as seen for plasma.
Excretion of radioactivity
It was hypothesized that binding of [14C]-oleic acid to for-
moline L112 in the gastrointestinal tract would result in an
increased excretion of radioactivity from the body via the
faeces and a lower accumulation of radioactivity in liver of
minipigs treated with formoline L112 (group B). In order to
investigate the effect of formoline L112 treatment on the
excretion of radioactivity, all animals receiving a single oral
dose of [14C]-oleic acid were housed in metabolic cages
suitable for the separate collection of urine and faeces at
24 h time intervals up to 144 h post-dose. Table 3 presents
Fig. 1 The mean time versus radioactivity concentration expressed as μg parent compound equivalents/g plasma of female Göttingen minipigs
after a single oral dose of [9-14C]-oleic to untreated animals and animals that were pre-treated with formoline L112 between 0 and 48 h post-dose.
The line with the open dots (○) (N = 5) represents the control group and the line with the filled dots (●) (N = 6) represents the formoline L112
pre-treated group. Error bars represent Standard Error of the Mean
Fig. 2 The individual time versus radioactivity concentration expressed as μg parent compound equivalents/g plasma of female Göttingen
minipigs after a single oral dose of [9-14C]-oleic to animals that were pre-treated with formoline L112 between 0 and 48 h post-dose. The lines
with the following markers ♦, ■, ▲, , ▬ and ● represent animal B1, B2, B3, B4, B5 and B6 of the formoline L112 pre-treated group, respectively
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the recoveries of radioactivity in excreta (urine & faeces),
liver and contents of the gastrointestinal tract at sacrifice of
untreated (control) and formoline L112 pre-treated female
Göttingen minipigs after a single oral dose of 10 mg/kg
[14C]-Oleic acid.
After 144 h post-dose only a part of the dosed radio-
activity is excreted with urine 1.33 % and 1.46 % and fae-
ces 6.51 and 7.15 %, for the untreated control animals of
group A and formoline L112 treated animals of group B,
respectively. At sacrifice the contents of the gastrointes-
tinal tract contained 0.08 and 0.13 % of the dosed
amount of radioactivity in group A and B, respectively.
The liver at sacrifice contained a similar amount of
radioactivity in both groups, namely 0.37 % of the dosed
amount of radioactivity. Most likely, the majority of the
dosed radioactivity is distributed into the body and/or
further metabolized into CO2.
Although the standard deviations are relatively high,
the excretion profile of radioactivity in urine and faeces
seemed a little bit delayed in the formoline L112 pre-
treated animals as compared to the untreated animals as
presented in Fig. 3. The observation that treatment with
formoline L112 did not affect the total excretion of
radioactivity with faeces, but only seems to delay the ex-
cretion slightly, is in line with the pharmacokinetic data.
The total area under the curve from start until the end
of the study (AUC0-144h) was 190 ± 38 h.μg/g and de-
creased non-significantly to 158 ± 32 h.μg/g over the
complete duration of the study. As animals only received
one oral dose of formoline L112, the effects are most
pronounced in the first period following dosing (0–
24 h), but fade away after receiving additional oleic acid
containing meals without formoline L112 treatment.
Altogether, these observations indicate that formoline
L112 reduces the bioavailability of [14C]-oleic acid be-
tween the 0–12 h, 0–24 h, 0–48 h and 0–60 h time in-
tervals due to a delayed absorption and most
interestingly prevents peak exposures of fatty acids in
the body.
Metabolite profiling of radioactivity in faeces
Reverse phase HPLC radiometric analysis was used to
investigate the profile of radioactivity in faeces for some
selected samples of untreated and formoline L112
treated animals, and to separate and distinguish [14C]-
oleic acid from its possible degradation products. The
radioactivity was extracted from faeces and the mean re-
covery of excretion was 84.2 %. Figure 4 presents a rep-
resentative radioactivity HPLC profile of faeces. The
excreted radioactivity was eluted as 3 peaks, the first
peak eluted at 12.1–14.7 min, the second peak eluted
around 17.7–20.4 min ([14C]-oleic acid) and the third
peak eluted at 23.4–24.7 min. There were no remarkable
differences in metabolic profile between the untreated
and formoline L112 treated animals.
Balancing and recovery of radioactivity
A full balancing of the administered radioactivity was
not given as the volatile matter was not trapped during
the test and as all organs, tissues and residual carcasses
of the minipigs were not collected and analysed for
radioactivity. A recovery and balance of the non-volatile
matter of collected samples is shown in Fig. 5. Here a
relevant difference between the untreated control group
Table 2 Pharmacokinetic parameters (non-compartmental analysis) of [9-14C]-oleic acid and/or its metabolites in plasma and blood
of Göttingen minipigs after a single oral dose of [9-14C]-Oleic to untreated minipigs (group A) and minipigs that were pre-treated
with 2 tablets of 500 mg formoline L112 (group B)
Group A B %a A B %a
Plasma Blood
Pharmacokinetic parameters
Tmax (h) 4 ± 3 16 ± 9* - 4 ± 3 14 ± 11 -
Cmax (μg/g) 14.1 ± 3.6 3.3 ± 1.2** 23.4 8.5 ± 2.2 2.1 ± 0.8** 24.7
AUC(0-12h) (h* μg/g) 65.6 ± 6.0 21.6 ± 14.0** 32.9 40.0 ± 4.8 13.3 ± 9.1** 33.3
AUC(0-24h) (h* μg/g) 98.4 ± 17.2 49.9 ± 20.8** 50.7 61.7 ± 13.1 29.8 ± 12.9** 48.3
AUC(0-48h) (h* μg/g) 136 ± 28 91.0 ± 23.2* 66.9 88.3 ± 19.0 56.9 ± 13.1* 64.4
AUC(0-60h) (h* μg/g) 148 ± 31 105 ± 25* 70.9 97.2 ± 20.6 67.3 ± 13.8* 69.2
AUC(0-72h) (h* μg/g) 157 ± 32 116 ± 26 73.9 105 ± 22 76.4 ± 14.2* 72.8
AUCall(0-144h) (h* μg/g) 190 ± 38 158 ± 32 83.2 139 ± 25 118 ± 16 84.9
Vz (g/kg) 7008 ± 2962 5629 ± 1946 - 8860 ± 1848 9515 ± 1647 -
Cl (g/h/kg) 40.7 ± 5.5 49.8 ± 8.3 - 48.4 ± 7.9 47.6 ± 7.3 -
MRTlast (h) 35.9 ± 1.8 50.2 ± 5.1** - 43.6 ± 3.1 58.4 ± 5.7** -
aPercentage of radioactivity remaining in plasma or blood following pre-treatment with formoline L112 compared to the untreated control group
* P ≤ 0.05, ** P ≤ 0.01
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A and the formoline L112 treated group B is clearly vis-
ible. As this study was not a mass-balance study because
of the abovementioned reason, the overall recovery was
34.7 and 17.9 % (based on the AUC0-12h) and 13.9 and
10.6 % (based on the Cmax) of the dosed amount of
radioactivity in the untreated and formoline L112 treated
minipigs, respectively.
Discussion
The current strategies to reduce the burden of obesity
and its consequences include lifestyle intervention
(diet/physical activity), pharmacotherapy, and bariatric
surgery.
At present, because of dissatisfaction with high costs
and potentially hazardous and/or embarrassing side-
effects of the current available therapies, the potential of
natural products like polyglucosamines for treating obes-
ity is discussed, and may serve an excellent alternative
strategy for treating obesity [3, 7]. Polyglucosamines
have been promoted as a fiber of natural origin that may
help reduce the absorption of fat due to its ability to
“bind” fat and bile salts in the human gastrointestinal
tract and pass this complexed fat-polyglucosamine mix-
ture out of the body. This action reduces absorbance of
dietary fat, and has prompted the use of these sub-
stances to help with weight loss [7]. The objective of this
study was to provide data on the influence of formoline
L112 on the bioavailability of [9-14C]-oleic acid as a
model compound in the adult female Göttingen minipig.
Upon treatment with formoline L112, the Tmax of [
14C]-
oleic acid in plasma was shifted from 4 to 16 h. The
Cmax decreased significantly from 14.1 μg/g to 3.3 μg/g
upon treatment with formoline L112. In addition, upon
treated with formoline L112 the internal exposure to
[14C]-oleic acid as reflected by the area under the curve
during the 0–12 h post-dose time interval (AUC0-12h), is
significantly decreased to 32.9 % of the plasma value of
[14C]-oleic acid in untreated animals. Even up to 24 h
post-dose, the AUC0-24h is significantly decreased to
50.7 % of the plasma value in untreated animals and this
significant effect is prolonged up to 60 h post-dose. In
the formoline L112 pretreated minipigs, a clear effect of
a partial stomach emptying was observed around the
time-points of feeding at start and end of the day,
around 8 and 24 h post-dose. This effect was not ob-
served for the untreated animals of group A. At the
second emptying period of the stomach, the binding
strength of formoline L112 for [14C]-oleic acid is clearly
still present.
In untreated subjects, oleic acid is absorbed practically
completely and is distributed in the organism after oral
administration [35, 36]. Breakdown via the pathways of
lipid metabolism takes place by successive β-oxidation
and excretion as CO2. Like other free fatty acids, oleic
acid is absorbed by the intestinal walls where it is con-
verted to triglycerides. The triglycerides are transported
in lipoproteins in serum or in chylomicrons in the
lymphatic vessels and are stored in adipose tissue or
metabolized. Thirtyone test persons with normal fat as-
similation were given oral doses of radioactively labelled
triolein and oleic acid; after 6 days they had excreted less
than 10 % of the substances in the faeces [37]. This pat-
tern is similar as has been observed in the present study.
Considerable evidence suggests that exposure to in-
creased free fatty acid concentrations plays a key role in
Table 3 Summary table of the mean recovery of radioactivity
([9-14C]-oleic acid and/or its metabolites) in excreta (urine, faeces
and cage wash), liver and contents of the gastrointestinal tract
of Göttingen minipigs after a single oral dose of [9-14C]-oleic to
untreated minipigs (group A) and minipigs that were pre-treated
with 2 tablets of 500 mg formoline L112 (group B). Data are
presented as the mean ± standard deviation
Sample Recovery expressed as % of the
applied dose
Group A Group B
Control (untreated) Formoline l112
Urine
-48–24 h 0.00 ± 0.01 0.00 ± 0.00
-24–0 h 0.01 ± 0.00 0.00 ± 0.00
0–24 h 0.79 ± 0.05 0.46 ± 0.28
24–48 h 0.28 ± 0.10 0.54 ± 0.14
48–72 h 0.09 ± 0.08 0.25 ± 0.17
72–96 h 0.08 ± 0.05 0.10 ± 0.04
96–120 h 0.05 ± 0.03 0.07 ± 0.04
120–144 h 0.03 ± 0.00 0.05 ± 0.02
Total 1.33 ± 0.20 1.46 ± 0.17
Faeces
-48–24 h 0.00 ± 0.00 0.00 ± 0.00
-24–0 h 0.00 ± 0.00 0.00 ± 0.00
0–24 h 0.02 ± 0.02 0.06 ± 0.06
24–48 h 2.22 ± 2.05 1.45 ± 1.94
48–72 h 3.21 ± 2.93 3.02 ± 1.43
72–96 h 0.85 ± 0.83 2.17 ± 2.21
96–120 h 0.15 ± 0.13 0.32 ± 0.16
120–144 h 0.06 ± 0.03 0.13 ± 0.09
Total 6.51 ± 2.88 7.15 ± 2.87
Cagewash 0.07 ± 0.07 0.10 ± 0.07
Total excreted (sum urine, faeces,
cagewash)
7.90 ± 3.13 8.72 ± 2.75
Liver at sacrifice (144 h post-dose) 0.37 ± 0.07 0.37 ± 0.03
GI-tract contents at sacrifice
(144 h post-dose)
0.08 ± 0.04 0.13 ± 0.06
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the pathogenesis of insulin resistance. Free fatty acids
cause both insulin resistance and inflammation in the
major insulin target tissues (skeletal muscle, liver and
endothelial cells) and thus are an important link between
obesity, insulin resistance, inflammation and the devel-
opment of type 2 diabetis, hypertension, dyslipidemia,
disorders of coagulation and atherosclerotic vascular
disease [38]. Reducing plasma FFA concentration in
obese and type 2 diabetic (T2DM) subjects improves
insulin sensitivity [39].
Endotoxin, the major constituent of the outer cell
membrane of gram negative bacteria, crosses the gut
mucosal membrane to enter the circulation and directly
stimulates inflammatory pathways. High-fat meals result
Fig. 3 Excretion profile of radioactivity in urine and faeces of female Göttingen minipigs after a single oral dose of [9-14C]-Oleic to group A
(control) and group B (minipigs pre-treated with a single oral dose of 2 tablets of 500 mg formoline L112 per animal). Open markers untreated,
closed markers treated. Open dots ○, filled dots ● represent the excretion of radioactivity with urine, open triangles ◊, and filled triangles ♦ represent
the excretion of radioactivity with faeces of group A and group B, respectively. Error bars represent Standard Error of the Mean
Fig. 4 Representative radioactivity HPLC profile of a faeces extract sample. The peak eluting at a retention time of 18.7 min represents
[9-14C]-oleic acid
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in an increase in endotoxin levels in animal and human
studies, with a greater increase in metabolic disease
states [40–42]. A high-fat diet constitutes one of the
major risks for developing obesity, diabetes, atheroscler-
osis, and other feeding-related disorders. Consumption
of a high fat diet induces inflammation in the adipose
tissue, liver, and skeletal muscle by increasing endotoxin
lipopolysaccharide levels in the intestinal lumen, as well
as by enhancing LPS action via Toll-like receptor 4. This
inflammation plays a critical role in the development of
obesity and insulin resistance [41, 43].
In the present study it has been demonstrated that for-
moline L112, which is used for weight management,
weight loss and to lower cholesterol blood levels, de-
creases peak levels of [14C]-oleic acid in plasma and also
reduces the overall internal exposure to [14C]-oleic acid.
Treatment with formoline L112 reduces (as judged by
Cmax & AUC) and delays (as judged by Tmax) fat absorp-
tion from the gastrointestinal tract into the systemic
circulation and limits peak exposure to free fatty acids
which may contribute to a more beneficial condition in
overweight humans.
According to the product information of formoline
L112, two tablets of 500 mg should be taken twice daily
with two main meals with the highest fat content, for
instance at breakfast and dinner. In the present study,
minipigs were only dosed once with formoline and did
not receive formoline L112 at the second meal on the
dosing day, thus it is expected that a second dose would
even reduce uptake to a higher extent.
In vitro tests performed by the supplier of the polyglu-
cosamine with a synthetic mixture of dietary oils and
lipids as model oil indicated no preference or discrimin-
ation of any fatty acid for interaction with formoline
L112 (unpublished).
Therefore, it is assumed that the effects of polygluco-
samine on the bioavailability of [14C]-oleic acid are
transferable to other fats.
Conclusion
In conclusion, treatment with the polyglucosamine formo-
line L112 reduces (as judged by Cmax & AUC) and delays
(as judged by Tmax) fat absorption from the gastrointes-
tinal tract into the systemic circulation and limits peak
exposure to free fatty acids which may contribute to a
more beneficial condition in overweight humans.
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Fig. 5 Individual and mean distribution and recovery of radioactivity in female Göttingen minipigs after a single oral dose of nominal 10 mg
[9-14C-oleic acid/kg in group A (control) and group B (minipigs pre-treated with a single oral dose of 2 tablets of 500 mg formoline L112 per
animal). Radioactivity is expressed as % parent compound. The following patterns , , and represent the amount of radioactivity in
blood (Cmax), liver, urine and faeces/gastrointestinal tract, respectively
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